Immupharma PLC - Directorate Change
ImmuPharma PLC
("ImmuPharma" or the "Company")
BOARD STRENGTHENED AHEAD OF NEXT PHASE OF COMPANY PROGRESSION
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides notification of changes to its Board of Directors.
It has been a pivotal 2023 for ImmuPharma, specifically within its P140 autoimmune platform.
Most recently in June, the Company announced that, after receiving comprehensive guidance from the Food & Drug Administration ("FDA") on the new Phase 2/3 adaptive clinical trial protocol for the lead programme for the treatment of patients with systemic lupus erythematosus ("SLE/Lupus"), it is moving forward with the study, together with its US partner Avion.
Positive progress on the P140 platform was also announced in May for a second high medical need disease, chronic idiopathic demyelinating polyneuropathy ("CIDP"). The Company received positive feedback from the FDA at a pre-IND meeting for a late-stage Phase 2/3 adaptive clinical program in patients, which is a further debilitating auto-immune condition within the Company's P140 platform.
In parallel with advancements in the late-stage clinical developments, the Company is also actively in discussions with a number of potential licensing partners for programmes across the Company's development portfolio.
In order to align with the new phase of progress, the Company recognised the need to add further skills and experience to the Board to ensure that we have the requisite Board composition for the next stage of evolution of the business.
We are therefore delighted to announce today the appointment of Dr
He is currently Vice President of Research & Investments, working with Royalty Pharma, a
Through his consulting practice (Acumen Life Science Investment Consulting)
We are also extremely pleased to welcome Dr
At this time, Dr
All Board changes take place with immediate effect.
Commenting on the Board changes,
"I am delighted to welcome Laurence to the Board. His deep centred experience of late-stage drug development, together with his international business development expertise, will perfectly complement with and support the executive management team and together will ensure that we have the essential skills and knowledge required for the next stage of ImmuPharma's evolution.
I am also extremely pleased to welcome Sébastien to the Board. Having now worked closely with Sébastien over the last 2 years and seen first-hand how he has added invaluable insight and clinical direction within our drug portfolio, his appointment will be an extremely positive addition to the Board.
We are now on a pivotal course for ImmuPharma. As a Board, we remain focused on bringing our two key late stage P140 clinical assets in Lupus and CIDP through their final clinical trials and to the market.
We also continue to concentrate on further commercial and partnering opportunities and with these new Board appointments believe this may be accelerated over the next period."
End
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE
Additional information:
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
Dr
|
Current directorships and/or partnerships |
Former directorships and/or partnerships (within the last five years): |
|
ImmuPharma France SA* Ureka Pharma SAS* FindMolecule Inc. Pharmanoviq SAS |
N/A |
*an ImmuPharma group company
Dr
|
Current directorships and/or partnerships |
Former directorships and/or partnerships (within the last five years): |
|
HEX Therapeutics LLP
Acumen Life Science Investment Consulting Limited |
N/A |
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE